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Mutationally corrupted cancer (stem) cells are the driving force of tumor development and progression. Yet,
these transformed cells cannot do it alone. Assemblages of ostensibly normal tissue and bone marrow-
derived (stromal) cells are recruited to constitute tumorigenic microenvironments. Most of the hallmarks of
cancer are enabled and sustained to varying degrees through contributions from repertoires of stromal
cell types and distinctive subcell types. Their contributory functions to hallmark capabilities are increasingly
well understood, as are the reciprocal communicationswith neoplastic cancer cells thatmediate their recruit-
ment, activation, programming, and persistence. This enhanced understanding presents interesting new
targets for anticancer therapy.The overarching focus of cancer research for the past four
decades has been on the malignant cancer cell, seeking to
understand the dominant oncogenes and tumor suppressor
genes whose respective activation/upregulation or loss of func-
tion serve to impart aberrant properties on normal cells, thus
contributing to their transformation into the cancerous cells
that form the basis for malignancy. New tools and new data
have continued to enrich our knowledge and insights into
properties of malignant cells and the genetic aberrations that
endow the proliferative foundation of cancer as a chronic
disease.Whole-genome resequencing and genome-wide epige-
netic and transcriptional profiling are presenting an avalanche of
new data, with great expectations and concomitant challenges
to distill it into a clarity of mechanism that can, in turn, be trans-
lated into more effective therapies. With rare exception, today’s
therapies for most forms of human cancer remain incompletely
effective and transitory, despite knowledge of driving oncogenes
and crucial oncogenic signaling pathways amenable to pharma-
cological intervention with targeted therapies. The challenge of
distillation is, in fact, even more daunting if one incorporates
the diversity of human cancers arising from distinctive cells of
origin in different tissues and organs, with variable parameters
of tumor development and progression, oncogenic mutation,
prognosis, and response to therapy.
The hallmarks of cancer (Hanahan and Weinberg, 2000) were
conceived to suggest a conceptual rationale—an underlying
commonality—for this diversity and disparity in cancer cell geno-
types and phenotypes, positing that the spectrum of cancers
reflects different solutions to the same challenge to a prospective
outlaw cell, being able to circumvent the intrinsic barriers and
protective functions that have evolved in higher organisms
to prevent unauthorized, chronic cell proliferation. A second
premise was the now-increasingly accepted importance of the
tumor microenvironment (TME), embodied in the concept that
cancer cells do not manifest the disease alone, but rather
conscript and corrupt resident and recruited normal cell typesto serve as contributing members to the outlaw society of cells.
Collaborative interactions between neoplastic cancer cells and
their supporting stroma coalesce into the ectopic, chronically
proliferative (and often disseminating) organ-like structures that
typify most human cancers, in the form of tumors and local inva-
sions, metastases, or vascular niches nurturing hematopoietic
malignancies. Thus, in the past decade, the TME and its constit-
uent ‘‘stromal’’ cells have collectively risen in prominence, now
embracing a broad field of investigation. While some aspects
of stroma have been long appreciated, in particular, the contribu-
tions of tumor angiogenesis and remodeled extracellular matrix
(ECM) (Bissell et al., 1982; Dvorak, 1986; Folkman, 1974), the
larger impact of the TME on tumor growth and progression,
and on the resilience of most cancers in the face of therapy, is
increasingly evident, but perhaps still not fully appreciated.
This perspective, therefore, seeks to document the diverse func-
tional contributions that stromal cell constituents of tumors can
make toward cancer phenotypes, by illustrating how different
stromal cell types demonstrably contribute to the core and
emergent hallmarks of cancer, namely, sustaining proliferative
signaling, evading growth suppressors, resisting cell death,
enabling replicative immortality, inducing angiogenesis, acti-
vating invasion and metastasis, reprogramming energy metabo-
lism, and evading immune destruction. As will be seen below,
stromal cells types are significantly influencing most of the hall-
mark capabilities, highlighting the realization that malignant
cancer cells, despite all their mutational entitlement, do not act
alone in elaborating the disease.
Contributions of Stromal Cell Types to Hallmark
Capabilities
While the contributions of certain stromal cell types to particular
hallmarks is self-evident, in particular, that of endothelial cells
to tumor angiogenesis, there are much broader contributions
of stromal cells to the hallmarks of cancer (and hence to the
nature of the disease). We present below illustrative but notCancer Cell 21, March 20, 2012 ª2012 Elsevier Inc. 309
Figure 1. Multifactoral Contributions of Activated/Recruited Stromal Calls to the Hallmarks of Cancer
Of the eight acquired hallmark capabilities—six core and two emerging (Hanahan and Weinberg, 2011)—seven demonstrably involve contributions by stromal
cells of the tumor microenvironment. The stromal cells can be divided into three general classes, depicted here by their involvement in particular hallmarks,
illustrating the diversity of their functional contributions. Notably, the importance of each of these stromal cell classes varies with tumor type and organ, governed
by parameters of the distinctive tumor microenvironments and underlying oncogenetic alterations in cancer cells and cancer stem cells that arise in primary
tumors, and their invasive andmetastatic colonizations. Moreover, distinctive cell types and subcell typeswithin these classes can exert variable roles in enabling
these capabilities, and in some cases by opposing them, as elaborated in the text and in Figure 2.comprehensive examples of the functional roles that stromal
cells play in enabling the various hallmark capabilities. Moreover,
while we recognize that within each stromal subtype a spectrum
of subpopulations exist, most notably in the case of cells in the
innate immune system (myeloid-lineage cells), for simplicity,
and to appeal to a general audience, we refer to these various
subgroups within the general population as opposed to discus-
sing activities of each, since comprehensive reviews describing
these intricacies are available (Chow et al., 2011; Gabrilovich and
Nagaraj, 2009; Mantovani et al., 2011; Porta et al., 2011). The
breadth of stromal cell contributions to hallmark capabilities is
illustrated in Figure 1, in which we have grouped the generic
constituents of the stromal component of the TME into three
general classes: angiogenic vascular cells (AVCs), infiltrating
immune cells (IICs), and cancer-associated fibroblastic cells
(CAFs).
Sustaining Proliferative Signaling
Although driving oncogenic mutations conveying chronic prolif-
erative stimuli in neoplastic cells are definitive for, and consid-310 Cancer Cell 21, March 20, 2012 ª2012 Elsevier Inc.ered essential to, many forms of human cancer, virtually every
stromal cell type has demonstrable ability to support hyperprolif-
eration of cancer cells in one context or another. As such, para-
crine and juxtacrine mitogenic signals supplied by stromal cell
types may potentially be involved in different tumor types at
virtually any stage of tumorigenesis and progression, ranging
from the initiation of aberrant proliferation to the development
of adaptive resistance to therapies targeting such driving onco-
genic signals.
Angiogenic Vascular Cells.Certainly themost well-established
extrinsic modulator of cancer cell (and thus tumor) growth is
lesional neovascularization (Folkman, 1974), involving the tube-
forming endothelial cells and their supporting pericytes that
comprise the angiogenic vasculature (Armulik et al., 2005). It
has long been evident in mouse models that the induction of
angiogenesis, the ‘‘angiogenic switch’’ (Folkman et al., 1989),
increases the rates of cancer cell proliferation in neoplasias
and tumors (Bergers et al., 1999; Hanahan and Folkman,
1996), and that inhibition of angiogenesis can impair such
hyperproliferation (Bergers et al., 1999; Brem et al., 1993;
Carmeliet and Jain, 2011; Ferrara and Alitalo, 1999; Parangi
et al., 1996; Shaheen et al., 1999), presumably reflecting reduced
bioavailability of blood-borne mitogenic growth factors, with or
without concomitant antiapoptotic survival factors (see below).
Notably, the (mitogenic) effects on cancer cells of angiogenic
switching and its inhibition in human tumors remains only
inferential, in large part due to a paucity of analyses involving
serial biopsies of lesions during malignant progression, and
throughout the course of therapeutic response and relapse/
resistance to angiogenesis inhibitors.
Recently, AVCs have been implicated in local supply of
growth-promoting trophic factors that are expressed and
secreted—independent fromblood-borne factors—by the endo-
thelial cells, potentially acting to stimulate in a paracrine fashion
multiple hallmark capabilities (Butler et al., 2010); the generality
and importance of such ‘‘nonvascular’’ local support of cancer
cell proliferation and other capabilities by tumor endothelial cells
(and pericytes) is yet to be established.
Infiltrating Immune Cells. Although ‘‘inflammation and cancer’’
has become a rubric for the intersection of tumors with the
immune system, many tumors show subtle infiltrations of
immune cells that do not meet the classical definition of an
inflammatory immune response, and yet are functionally instru-
mental in the tumor phenotypes discussed below; thus, we
adopt the terminology of IICs to encompass both classic inflam-
mation and more subtle involvement of immune cells in the TME.
That said, virtually all adult solid tumors (carcinomas most
notably) contain infiltrates of diverse leukocyte subsets including
both myeloid- and lymphoid-lineage cells (Tlsty and Coussens,
2006), whose complexity and activation status vary depending
on the tissue/organ locale, and stage of malignancy (Mantovani
et al., 2008; Ruffell et al., 2011). IICs supply direct and indirect
mitogenic growth mediators that stimulate proliferation of
neoplastic cells, as well as other stromal cell types in their vicinity
(Balkwill et al., 2005). Notable examples include epidermal
growth factor (EGF), transforming growth factor-b (TGF-b),
tumor necrosis factor-a (TNF-a), fibroblast growth factors
(FGFs), various interleukins (ILs), chemokines, histamine, and
heparins (Balkwill et al., 2005). In addition, IICs express diverse
classes of proteolytic enzymes (metallo, serine, and cysteine
proteases) that can selectively cleave and thereby modify the
structure and function of extracellular matrix (ECM), for example,
uncaging bioactive mitogenic agents (Lu et al., 2011a). While
such effects are reflective of typical leukocyte activities ascribed
to repair of tissue damage (Dvorak et al., 2011; Tlsty and Cous-
sens, 2006), the chronic presence of paracrine and juxtacrine
mitogenic signaling molecules provided by IICs can supply
evolving neoplastic cells with signals that help sustain their
unchecked proliferation.
A recent study (Guerra et al., 2011) adds another intriguing
contribution of IICs to the proliferative hallmark, demonstrating
that inflammation of a pancreas harboring ductal epithelial cells
with an activating mutation in the K-ras oncogene can obviate
triggering of oncogene-induced cell senescence that otherwise
limits hyperproliferation and malignant progression of nascent
(initiated) pancreatic cancer cells; treatment of such cancer-pre-
disposed mice with anti-inflammatory drugs restores oncogene-
induced senescence, and impairs development of pancreaticcancer. The identity of the immune cell (sub)-type and of the
paracrine signal(s) it supplies to inhibit oncogene-induced
senescence remain to be elucidated, as does the potential
involvement in other tumor types of this microenvironmental
mechanism for circumventing senescence barriers to onco-
gene-driven hyperproliferation.
Cancer-Associated Fibroblastic Cells. Likely also reflecting
corruptedwound healing and tissue repairmechanisms, a variety
of fibroblastic cells can be recruited and/or activated to
contribute to this and other hallmark capabilities (for recent
reviews, see Cirri and Chiarugi, 2011; Franco et al., 2010; Pietras
andOstman, 2010; Ra¨sa¨nen and Vaheri, 2010). Thus, connective
tissue fibroblasts proximal to neoplastic growths can be acti-
vated, and mesenchymal progenitors—in particular, mesen-
chymal stem cells (MSCs), both local and bone marrow
derived—can be recruited and induced to differentiate into
myofibroblasts defined in part by expression of alpha smooth
muscle actin (aSMA) (Paunescu et al., 2011), or into adipocytes
defined by expression of fatty acid binding protein-4 (FABP4)
(Rosen and MacDougald, 2006). We group these similarly fibro-
blastic and yet distinctive cell types into a stromal cell class
collectively referred to as CAFs (Hanahan and Weinberg, 2011,
and references therein). Each of these CAF subtypes can
contribute to a variety of tumor-promoting functions, with the
potential to impact on multiple hallmark capabilities; their diver-
sity in characteristics and in functional contributions in different
organ-specific TMEs are increasingly well delineated, and
appreciated. Thus, for example, CAFs can express and secrete
signaling proteins that include mitogenic epithelial growth
factors—hepatocyte growth factor (HGF), EGF family members,
insulin-like growth factor-1 (IGF-1), stromal cell-derived factor-1
(SDF-1/CXCL12), and a variety of FGFs—with the capability to
stimulate cancer cell proliferation (Cirri and Chiarugi, 2011;
Erez et al., 2010; Franco et al., 2010; Kalluri and Zeisberg,
2006; Orimo et al., 2005; Ra¨sa¨nen and Vaheri, 2010; Rosen
and MacDougald, 2006; Spaeth et al., 2009). CAFs can also
orchestrate functional attributes associated with epithelial-to-
mesenchymal transition (EMT) via secretion of TGF-b (Chaffer
and Weinberg, 2011), which can also affect other hallmark traits
noted below. In addition, both activated adipocytes and acti-
vated fibroblasts can express spectrums of ‘‘proinflammatory’’
mediators (Celis et al., 2005; Dirat et al., 2011; Erez et al.,
2010), thereby recruiting and activating IICs that, in turn, provide
mitogenic signals to cancer cells, as well as other cell types in the
TME. The signals that activate, recruit, and ‘‘fine-tune’’ or
‘‘educate’’ CAFs are complex and variable between different
tumor types, as are the particular roles they are implicated to
play, in particular, TMEs, mirroring the complexity of IICs and
of the oncogenic transformation events andmutational ontogeny
of the cancer cells.
Evading Growth Suppressors
Although suppression of unscheduled/chronic proliferation of
incipient cancer cells is largely thought to involve cell intrinsic
mechanisms, principally involving the p53 and pRb tumor
suppressor pathways, there are intriguing examples of stromal
cells in the TME helping cancer cells evade various forms of
growth suppression, as illustrated by the following examples.
Cancer-Associated, and Normal, Fibroblastic Cells. The roster
of induced gains of function that enable CAFs to support multipleCancer Cell 21, March 20, 2012 ª2012 Elsevier Inc. 311
hallmark tumor phenotypes does not currently include paracrine
factors that demonstrably short-circuit cancer cell-intrinsic
growth suppressor pathways. There is, however, compelling
evidence for causal loss of function elicited during the conver-
sion of normal fibroblasts into CAFs. Experiments performed in
coculture systems have clearly demonstrated that normal
connective tissue fibroblasts (but not CAFs) from various organs
can inhibit growth of cancer cells, in a process that requires
contact of the ‘‘normal’’ fibroblasts with cancer cells, suggestive
of roles (along with epithelial contact inhibition) in governing
epithelial homeostasis and proliferative quiescence (Bissell and
Hines, 2011; Flaberg et al., 2011). Thus, ‘‘normal’’ fibroblasts
may serve as extrinsic epithelial growth suppressors, such that
CAFs contribute to this particular hallmark capability by what
they have lost from their cell of origin during the course of being
reprogrammed (‘‘educated’’) as CAFs. An additional possibility,
currently speculative, is that tissue fibroblasts activated into
CAF-like states by other aberrant conditions (e.g., fibrosis,
edema, or infection) might also produce proteases or other para-
crine factors that disrupt normal epithelial architecture, thereby
relieving the intrinsic growth suppression mediated by epithelial
cell-cell adhesion, allowing initiation of neoplastic development.
Infiltrating Immune Cells. Epithelial cells are subject to an
extrinsic form of growth suppression involving cell-cell and
cell-ECM adhesionmolecules that via their adhesive interactions
transmit antigrowth signals to the cell cycle machinery; such
antigrowth signals can, for example, overrule the proliferation-
inducing signals of driving oncogenes such as c-Myc (Hezel
and Bardeesy, 2008; Partanen et al., 2009). IICs express and
secrete a variety of proteolytic enzymes (metallo, serine, and
cysteine proteinases and heparanase) that, in addition to liber-
ating mitogenic growth factors, can selectively cleave cell-cell
and cell-ECM adhesion molecules, and/or ECM molecules
(ligands for the latter), thereby disabling growth suppressing
adhesion complexes maintaining homeostasis (Lu et al.,
2011a; Mohamed and Sloane, 2006; Pontiggia et al., 2011; Xu
et al., 2009).
Resisting Cell Death
Tissues are endowed with embedded regulatory programs for
controlling aberrant proliferation of resident cells, as well as for
inhibiting ‘‘invasion’’ of foreign cell types, which act by inducing
one form or another of cell death, of which apoptosis is the most
prominent. Thus, in order to sustain their proliferative capacity
and thrive ectopically, neoplastic cells must either develop
intrinsic resistance to local cell death programs or instead coor-
dinate development of cell extrinsic programs that safeguard
their survival. Recent investigations have revealed the stromal/
extrinsic capabilities for evading the tissue-protective mission
of cell death programs that not only foster ectopic proliferation
and survival of neoplastic cells, but also help to blunt effective-
ness of cytotoxic and targeted therapy.
Angiogenic Vascular Cells. It is well established that vascular-
ization of incipient neoplasias and tumors serves to attenuate
cell death that would otherwise result from hypoxia and lack of
serum-derived nutrients and survival factors. Indeed, the afore-
mentioned studies from the 1990s report reduced apoptosis
scaling hand-in-hand with increased proliferation of cancer cells
following activation of the angiogenic switch, and conversely
increased apoptosis resulting from pharmacological or genetic312 Cancer Cell 21, March 20, 2012 ª2012 Elsevier Inc.impairment of angiogenesis. Induction of both apoptosis and
necrosis are almost invariable results of appreciable destruction
of tumor vasculature, as contrasted to the alternative ‘‘normali-
zation’’ of the tumor vasculature that results from weaker inhib-
itors of tumor angiogenesis and neovascularization (De Bock
et al., 2011; Goel et al., 2011). The role of angiogenesis in limiting
apoptosis is aptly illustrated by the effects of vascular disrupting
agents that destroy the tumor vasculature, causing acute
hypoxia and rampant cell death inside treated tumors, leaving
behind hollow acellular cores enveloped by a rim of viable cells
that survive by co-opting adjacent tissue vasculature (Daenen
et al., 2009). Such studies establish vascularization, be it
‘‘abnormal’’ or ‘‘normalized,’’ as essential to the hallmark capa-
bility for limiting cancer cell death.
Infiltrating Immune Cells. Heterotypic and homotypic cell
adhesion molecules provide various cell types—in their proper
tissue microenvironments (e.g., organized epithelia) —with
survival signals that help to maintain tissue integrity and homeo-
stasis, such that cell detachment and loss of adhesion triggers
apoptosis. One mechanism used by cancer cells to become
independent of such dependence on homotypic survival signals
involves IICs, which by binding to cancer cells take the place of
their disconnected epithelial brethren, conveying on them the
ability to survive in ectopic microenvironments by suppressing
the triggering of cell death pathways. Thus, for example, a4-
integrin-expressing tumor-associated macrophages (TAMs)
act in a juxtacrine manner to promote survival of metastatic
breast cancer cells in lung by binding vascular cell adhesion
molecule-1 (VCAM-1) expressed on breast cancer cells. The
a4-integrin/VCAM-1 interaction specifically activates Ezrin—
a mediator of receptor tyrosine signaling—in breast carcinoma
cells, which, in turn, induces PI3K/AKT signaling and suppres-
sion of apoptosis (Chen et al., 2011). A similar mechanism fosters
expansion of macrometastatic breast cancer in bone (Lu et al.,
2011c). In addition, TAMs also protect breast cancer cells from
chemotherapy (taxol, etoposide, and doxorubicin)-induced cell
death by a cathepsin protease-dependent mechanism (Shree
et al., 2011). Collectively, these studies reveal the capability of
macrophages (and monocytes) to provide survival signals to
cancer cells that limits the impact on neoplastic progression of
cancer cell death programs triggered by a variety of tissue-
protective and therapy-induced mechanisms.
Cancer-Associated Fibroblastic Cells. A number of studies
have implicated CAFs in the capability to limit the impact on
tumor growth and progression of cancer cell apoptosis (Kalluri
and Zeisberg, 2006; Loeffler et al., 2006; Pietras and Ostman,
2010). Onemodality involves the secretion of diffusible paracrine
survival factors such as IGF-1 and IGF-2. A second relates to
synthesis of ECM molecules and ECM-remodeling proteases
that contribute to formation of a neoplastic ECM, distinctive
from normal tissue stroma, that provides nondiffusible survival
signals (e.g., ligands for antiapoptotic integrins); functional
studies have implicated CAF-derived ECM in modulating cancer
cell survival, among other traits (Lu et al., 2011a). Moreover,
cancer-associated adipocytes, analogous to IICs, blunt the
cytotoxic effects of radiation therapy and confer a radioresistant
phenotype to breast cancer cells dependent on adipocyte-
derived IL-6 (Bochet et al., 2011). While the generality (and rele-
vance to human tumors) of these prosurvival effects has yet to be
established, it can be envisioned that such contributions by
CAFs will prove to be operative in many forms of human cancer,
and may also have differential clinical implications for individual
patients with the same tumor type, such as obese patients
whose cancers have been associated with more aggressive
characteristics (Khandekar et al., 2011).
Enabling Replicative Immortality?
Stabilizing telomere length and functionality to enable limitless
replication of cancer cells is the essence of this hallmark, one
that is seemingly independent of the TME, in that there is
currently no substantive evidence for stromal contributions to
telomere stabilization in cancer cells. While it could be argued
that abrogation of senescence-inducing signals from normal
stromal fibroblasts or antagonistic IICs is involved in enabling
this hallmark, we consider that triggering such senescence is
more likely involved in a first line of tissue defense focused on
opposing (along with cell death and cell cycle arrest) inappro-
priate proliferation, long before replicative immortality becomes
a factor, and thus stromal involvement in senescence and its
circumvention is most logically associated with the proliferation
and growth suppression hallmarks.
Inducing Angiogenesis
In adult tissues, most blood vessels are quiescent, and angio-
genesis (growth of new blood vessels from pre-existing ones)
occurs only during the female reproductive cycle and under
certain pathophysiological conditions, such as tissue remodel-
ing associated with wound healing (Carmeliet and Jain, 2011).
Whereas the cellular and molecular programs are common to
both physiological and tumor angiogenesis, constitutively acti-
vated proangiogenic signaling in tumorsmake tumor-associated
vessels distinctly irregular, chaotic, and inherently unstable (De
Bock et al., 2011; McDonald and Choyke, 2003; Morikawa
et al., 2002). Interestingly, tumors with reduced levels of such
hyperactive angiogenic stimulation—resultant to limited abun-
dance of vascular endothelial growth factor (VEGF) and other
angiogenic regulatory factors in their TME, or to pharmacological
suppression of VEGF—evidence so-called ‘‘vascular normaliza-
tion,’’ in which vessels are less torturous, with better pericyte
coverage, and improved and less erratic blood flow (De Bock
et al., 2011; Goel et al., 2011; Jain, 2005). Historically, tumor
angiogenesis was envisioned to be principally regulated by
cancer cells expressing proangiogenic factors, which is indeed
one mechanism; there is, however, now abundant evidence
that stromal cells in the TME are instrumental in switching on
and sustaining chronic angiogenesis in many tumor types, as
illustrated in the following examples.
Infiltrating Immune Cells. There is a tight interplay between
IICs and vascular cells. Endothelial cells mediate leukocyte
recruitment by expressing a repertoire of leukocyte adhesion
molecules, while IICs produce a diverse assortment of soluble
factors that influence endothelial cell behavior. Myeloid cells
implicated in these interactions include subsets of granulocytes
(neutrophils, basophils, and eosinophils), dendritic cells, TAMs,
Tie2-expressing monocytes, immature myeloid cells (iMCs)/
myeloid-derived suppressor cells (MDSCs), and mast cells.
The soluble mediators produced by IICs implicated in regulating
aspects of the angiogenic process include cytokines (VEGF,
bFGF, TNF-a, TGF-b, platelet-derived growth factor [PDGF],
placental growth factor [PIGF]), Neuropilin-1, chemokines(CXCL12, IL-8/CXCL8), matrix metalloproteinases (MMPs,
including MMP-2, -7, -9, -12, and -14), serine proteases (uroki-
nase-type plasminogen activator), cysteine cathepsin prote-
ases, DNA-damaging molecules (reactive oxygen species),
histamine, and other bioactive mediators (nitric oxide). All of
these effectors have demonstrated capabilities to regulate
vascular cell survival, proliferation, andmotility, along with tissue
remodeling, culminating in new vessel formation (De Palma and
Coussens, 2008).
TAMs regulate tumor angiogenesis largely through their
production of VEGF-A; this connection is illustrated by restora-
tion, via ectopic VEGF overexpression, of tumor angiogenesis
otherwise impaired by macrophage depletion (Lin et al., 2007).
Conversely, genetic deletion of the VEGF-A gene in macro-
phages attenuates tumor angiogenesis and results in a morpho-
logically more normal vasculature, much as is seen with pharma-
cological inhibitors of VEGF signaling (Stockmann et al., 2008). In
some mouse models of cancer, production of MMP-9 by TAMs
increases bioavailability of otherwise limited (ECM sequestered)
VEGF-A, thus providing an alternative, but still VEGF-dependent
route for promoting angiogenesis (Bergers et al., 2000; Du et al.,
2008; Giraudo et al., 2004). Similarly, TAM production of the
VEGF family member PIGF stimulates angiogenesis in some
tumors (Rolny et al., 2011) and thus TAMs may present a mech-
anism for acquiring resistance to anti-VEGF-A/VEGFR therapies
(Fischer et al., 2007; Motzer et al., 2006; Willett et al., 2005).
The significance of TAMs as anticancer therapeutic targets
has recently been emphasized by several studies reporting
that reprogramming of tumor-promoting TAMs toward a pheno-
type embodied in conventional ‘‘antigen-presenting’’ macro-
phages can blunt tumor growth via processes that include
impaired angiogenesis and vascular normalization. For example,
histidine-rich glycoprotein HRG, a host-produced protein
deposited in tumor stroma, can induce such a reprogramming
of TAMs, resulting in vascular normalization and improved
responses to chemotherapy (Rolny et al., 2011). Similar findings
were reported by blockade of colony stimulating factor-1
(CSF-1) signaling, which resulted in macrophage depletion in
mammary tumors, concomitant with reduced vascular density
and improved responses to chemotherapy (Denardo et al.,
2011). Common to both studies was enhanced anti-tumor
immune responses by cytotoxic T lymphocytes (CTLs), thus indi-
cating the complexity of dialogs by diverse stromal cell types in
tumors, and the power of targeting one subtype to thereby
subvert or alter bioactivities of other counterpart stromal cells.
While not as well studied, mast cells have long been recog-
nized for their ability to foster tumor angiogenesis (Kessler
et al., 1976). Recruitment of mast cells to human papilloma
virus-induced squamous carcinomas (Coussens et al., 1999) or
Myc-induced pancreatic b cell tumors (Soucek et al., 2007) is
required for macroscopic tumor expansion; treatment with
mast cell inhibitors results in impaired induction and persistence
of angiogenesis, thereby elevating hypoxia and cell death of both
cancer cells and endothelial cells (Soucek et al., 2007). Mast
cells are reservoirs of potent vascular mediators including
VEGF, Angiopoietin-1, IL-8/CXCL8, histamine, and heparin;
mast cells can also release proteases (e.g., MMP-9) that liberate
ECM-sequestered proangiogenic growth factors (Bergers et al.,
2000; Coussens et al., 1999), or indirectly regulate AVCs—in theCancer Cell 21, March 20, 2012 ª2012 Elsevier Inc. 313
case of tryptase—via cleavage of protease-activated receptor-2
(PAR2) on CAFs, which activates proangiogenic signaling
programs (Khazaie et al., 2011).
Other IICs associatedwith tumor angiogenesis include neutro-
phils and their myeloid progenitors, which produce MMP-9 and
are demonstrably involved in angiogenic switching in some
tumors (Nozawa et al., 2006; Pahler et al., 2008; Shojaei et al.,
2007), and platelets, the enucleatedminicells spun off frommeg-
akeryocytes whose principle role involves induction of blood
clotting in response to bleeding. Platelets release distinctive
granules containing either pro- or antiangiogenic regulatory
molecules, and have been implicated in angiogenesis for
decades (Sabrkhany et al., 2011); the precise roles and impor-
tance of platelets and themechanisms of their regulated degran-
ulation has been elusive. Recent studies however have reported
that candidate effectors in platelets can be genetically manipu-
lated (Labelle et al., 2011), thus enabling an avenue to clarify their
roles in tumor angiogenesis.
Cancer-Associated Fibroblastic Cells. There is abundant
evidence that CAFs are involved in orchestrating tumor angio-
genesis in a variety of tumor types. First, CAFs in different
TMEs can produce a number of proangiogenic signaling pro-
teins, including VEGF, FGF2 plus other FGFs, and IL-8/CXCL8
and PDGF-C; of note, PDGF-C may rescue angiogenesis in
some anti-VEGF resistant tumors (Crawford et al., 2009). In addi-
tion, CAFs as well as normal connective tissue fibroblasts are
major biosynthetic sources of ECMproteins, in which angiogenic
growth factors are sequestered. In contrast to typical normal
fibroblasts, CAFs can also produce a variety of ECM-degrading
enzymes that release such latent angiogenic factors (bFGF,
VEGF, TGF-b), rendering them bioavailable to their receptors
on endothelial cells (Kalluri and Zeisberg, 2006; Pietras and
Ostman, 2010; Ra¨sa¨nen and Vaheri, 2010). Finally, CAFs can
produce chemoattractants for proangiogenic macrophages,
neutrophils, and other myeloid cells, thereby indirectly orches-
trating tumor angiogenesis (Ra¨sa¨nen and Vaheri, 2010; Vong
and Kalluri, 2011), as well as directly stimulating recruitment of
endothelial precursor cells via secretion of CXCL12 (Orimo and
Weinberg, 2007).
Activating Invasion and Metastasis
All three classes of stromal cell are implicated as contributors in
one context or another to the capability for invasion and metas-
tasis, as the following examples illustrate.
Angiogenic Vascular Cells. The characteristics of chronically
angiogenic (and morphologically abnormal) tumor vasculature
have the added effect of contributing to cancer cell dissemina-
tion in the course ofmetastasis. Many tumors express high levels
of the proangiogenic factor VEGF, also known and first identified
as vascular permeability factor (Senger et al., 1983). VEGF
signaling through VEGFR2 loosens tight junctions interconnect-
ing endothelial tube cells, rendering vasculature permeable to
leakage of blood into the interstitial TME, and concomitantly
lowering barriers for intravasation of cancer cells into the circula-
tion, particularly in tumors with high interstitial fluid pressure,
which therefore counteracts pressure inside the vasculature.
Tumor vasculature hyperstimulated by VEGF often has reduced
pericyte coverage and looser association of such pericytes with
endothelium, the significance of which has been revealed in
studies where genetic or pharmacologic perturbation of pericyte314 Cancer Cell 21, March 20, 2012 ª2012 Elsevier Inc.coverage facilitates metastatic dissemination of cancer cells
(Cooke et al., 2012; Xian et al., 2006). Hypoxia in and around
tumor vessels also contributes to metastatic dissemination of
cancer cells through the actions of genes regulated by hypoxia
inducible (HIF) transcription factors, including VEGF and induc-
ible nitric oxide synthase (iNOS), among many mediators.
Notably, differential expression of HIFs by endothelial cells
(and IICs) is particularly significant for metastasis (Branco-Price
et al., 2012; Takeda et al., 2010), as they variably alter vascular
tension and function, largely dependent on nitric oxide, which,
in turn, loosens pericyte coverage (Kashiwagi et al., 2005),
contributing thereby to metastatic success. Such studies estab-
lish the concept, still to be generalized, that impaired vascular
integrity disables a significant barrier to blood-borne metastasis,
and thus facilitates dissemination of cancer cells from primary
human tumors.
The vasculature plays a similar role in metastatic seeding at
distant sites, where an intact normal endothelium with intimate
pericyte coverage can be envisaged to block cancer cell extrav-
asation from the blood into normal parenchyma. Indeed, it is
increasingly evident that metastatic primary tumors can precon-
dition the vasculature in metastatic sites with factors such as
VEGF, supplied systemically or produced locally by the dissem-
inated cancer cells they spawn; the actions of VEGF on the endo-
thelium at incipient metastatic sites facilitates both loosening of
vessel walls for extravasation, and subsequent induction of
angiogenesis to support metastatic tumor growth. Still to be clar-
ified is the identification and possible roles of factors produced
by endothelial cells and pericytes that contribute to metastatic
processes.
Infiltrating Immune Cells. Functional studies spanning the last
decade have unambiguously established and elaborated the
roles of IICs in fostering metastasis. Mast cells and macro-
phages in primary tumor TMEs provide a wide range of prote-
ases, including serine, cysteine, and metalloproteases (Kessen-
brock et al., 2010; van Kempen et al., 2006) that foster ectopic
tissue invasion by remodeling structural components of ECM
(fibrillar collagens, elastins, or fibrin), which in turn provide
conduits for malignant cell egress, as well as generating ECM
fragments with proinvasive signaling activities. For example,
the proteolytic activities of MMP-2 expressed by macrophages
and other leukocytes effects the release of cryptic ECM frag-
ments by cleaving laminin-5 g2 chains that, in turn, mimic EGF
receptor (EGFR) ligands and thus induce cell motility and inva-
sion (Giannelli et al., 1997; Pirila¨ et al., 2003). Leukocyte-derived
MMP-7 processes proheparin-bound-EGF (HB-EGF) into its
bioactive form in pancreatic carcinoma cells (Cheng et al.,
2007), resulting in repressed E-cadherin-mediated cell adhesion
and potentiation of invasive growth (Wang et al., 2007a). Leuko-
cyte-derived MMP-7 and cathepsin B further facilitate tumor
cell motility and invasion by directly cleaving extracellular
domains of E-cadherin (Gocheva et al., 2006; Vasiljeva et al.,
2006). IIC-derived TNF-a enhances invasive/migratory pheno-
types of breast, skin, and ovarian cancer cells through activation
of downstream signaling cascades, including the Jun N-terminal
kinase (JNK) and nuclear factor kB (NFkB) transcription factors,
resulting in induced gene expression of proinvasive factors, e.g.,
EMMPRIN (extracellular matrix metalloprotease inducer) and
MIF (migration inhibitory factor), whose expression enhances
MMP-2 and MMP-9 secretion and activity (Balkwill, 2009).
Macrophage-derived TNF-a also potentiates Wnt/beta-catenin
signaling during gastric carcinogenesis by activating Akt
signaling and GSK3beta phosphorylation in initiated gastric
epithelial cells independent of the NFkB pathway (Oguma
et al., 2008).
IIC mediators also inhibit expression of known metastasis
suppressor genes. T cells and macrophages infiltrating prostate
cancers produce the TNF-a-related cytokine RANKL (Receptor
Activator for NFkB Ligand). RANKL, through interaction with its
receptor RANK, activates Inhibitor of NFkB Kinase a (IKKa),
leading to transcriptional repression of the metastatic tumor
suppressor gene maspin (Abraham et al., 2003; Sager et al.,
1997); maspin inhibits metastasis by impairing cancer cell inva-
sion, in part by altering expression of integrin adhesion mole-
cules that anchor and thereby restrict cell mobility (Chen and
Yates, 2006). Abrogation of IKKa activity restores maspin gene
expression and significantly reduces lymphatic and pulmonary
metastasis of prostatic tumor cells, further strengthening the
causality link (Luo et al., 2007). Notably, in prostate cancer
metastasis to bone, RANKL bioavailability, and hence suppres-
sion of mapsin in cancer cells, is regulated by osteoclast-
supplied MMP-7, illustrating another means by which stromal
cells in metastatic microenvironments can provide paracrine
support for metastatic colonization (Gorden et al., 2007; Lynch
et al., 2005).
Concentration gradients of growth factors established by
leukocytes also coordinate tumor cell movement toward, and in-
travasation into, tumor-associated vasculature. For example,
macrophages are the primary source of EGF in the developing
mammary gland and in mouse models of breast cancer (Leek
et al., 2000; Lewis and Pollard, 2006). EGF promotes invasion/
chemotaxis and intravasation of breast carcinoma cells through
a paracrine loop operative between tumor cells and macro-
phages that are required for mammary cancer cell migration
(Wyckoff et al., 2004) via cofilin-dependent actin polymerization
(Wang et al., 2007b). Transcriptome profiling has revealed that
the TAMs participating in this paracrine interplay represent
a unique subpopulation that associates intimately with tumor
vessels (Ojalvo et al., 2010).
Long suspected but largely below the radar are platelets. A
recent report solidified these suspicions (Labelle et al., 2011),
revealing that platelets induce a transitory EMT by physically
associating with blood-borne cancer cells, facilitating extravasa-
tion and seeding of metastases. Functional genetic studies
demonstrated that the invasion- and metastasis-promoting
activity of platelets involves platelet-derived TGF-ß ligand as
well as an inducer of NFkB signaling that requires physical
contact of platelets with cancer cells (suggestive perhaps of
the membrane-bound Notch ligands). Thus, platelets can be
added to the roster of tumor-promoting hematopoietic cells
that facilitate invasion and metastasis. It is intriguing to consider
the possibility that platelets might intravasate into premalignant
tissues or primary tumors via leaky tumor vasculature, contrib-
uting therein to induction of EMT and locally invasive growth.
Cancer-Associated Fibroblastic Cells. There are increasing
examples wherein CAFs modulate the capability of cancer cells
to invade locally or establish secondary tumors at distant meta-
static sites. One prominent CAF-derived effector of this capa-bility is the c-Met ligand HGF, which stimulates via heightened
c-Met signaling both invasiveness and proliferation. A second,
CAF-derived effector, TGF-b, is demonstrably involved in acti-
vating EMT programs in certain cancer cells, thereby enabling
their capability for invasion and metastasis (Chaffer and Wein-
berg, 2011); likely additional CAF mediators will prove to be
involved in different contexts; thus, for example, CAF/MSC
secretion of CCL5 stimulates breast cancer metastasis (Karnoub
et al., 2007). Moreover, CAFs produce a distinctive (from normal
fibroblasts) repertoire of ECM proteins as well as a variety of
ECM remodeling enzymes that further modify the TME,
rendering it more supportive of cancer cell invasion, both prox-
imal to the CAFs as well in adjacent normal tissue (Chaffer and
Weinberg, 2011; Cirri and Chiarugi, 2011; Kalluri and Zeisberg,
2006; Pietras and Ostman, 2010). CAFs are detected at the
invasive fronts in some tumors, consistent with an active collab-
oration with cancer cells in invasion; such CAFs may reflect
comigrating cells as well as normal tissue fibroblasts that
have been reprogrammed by signals (e.g., PDGF and sonic
hedgehog) released by cancer cells (or IICs). Such reprogram-
ming is also evident in metastasis, where emigrating cancer cells
induce expression of the ECM molecule periostin, necessary for
efficient colonization in a mouse model of metastatic breast
cancer (Malanchi et al., 2012). In another model system, cancer
cells disseminate through the circulation in conjunction with
primary tumor-derived CAFs (Duda et al., 2010), bringing the
foundations of a TME to the metastatic site, a variation on the
theme discussed above whereby cancer cells disseminate in
association with macrophages or other myeloid cells.
Given the observations that fibrotic breast disease and
increased breast density predispose to breast cancer, and that
environmentally induced fibrotic disorders increase incidence
of lung, skin, and pancreatic cancer, it is evident that the intensity
of fibroblastic proliferation, accumulation and assembly may
play other influential roles in tumor development and progres-
sion. Breast carcinogenesis is accompanied by lysyl oxidase-
mediated crosslinking of collagen fibrils (largely produced by
CAFs) that imparts a proinvasive phenotype on mammary
cancer cells, which is dependent on enhanced PI3 kinase
(PI3K) signaling, and associated with integrin clustering and
increased presence of focal adhesions (Levental et al., 2009).
Notably, genetic or pharmacological blockade of lysyl oxidase-
mediated collagen crosslinking impedes late-stage cancer
progression in mouse models of mammary carcinogenesis
(Levental et al., 2009). Moreover, ablation of CAFs with an inhib-
itor of hedgehog signaling improves therapeutic delivery of
cytotoxic drugs in a mouse model of pancreatic ductal adeno-
carcinoma, revealing that the desmoplastic stroma erected by
CAFs represents a barrier to effective biodistribution of chemo-
therapy (Olive et al., 2009). The structural effects of CAFs on
TMEs have been further revealed by studies perturbing other
CAF-derived mediators. Notably, inhibiting either TGF-b, its
type I receptor (Kano et al., 2007; Sounni et al., 2010), or the
PDGF receptors (Pietras et al., 2001) similarly reduces interstitial
fluid pressure in certain tumors, resulting in improved tumor
hemodynamics and more favorable biodistribution of drugs, so
too does reducing the abundance of the ECM component
hyaluronic acid in the TME (Provenzano et al., 2012). Thus, in
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phenotypes, CAFs can profoundly alter the physical parameters
of the TME in some tumor types, consequently impacting
delivery of therapeutics.
Evading Immune Destruction
Angiogenic Vascular Cells. Although the aberrant morphology of
the angiogenic tumor vasculature—loosened interconnections
between endothelial cells and less intimate association and
coverage by pericytes—evidently facilitates transit of cells
across the vascular wall in both directions, there is abundant
evidence that such routes of transit are inmany cases insufficient
for the massive influx of natural killer (NK) cells, CTLs, and NK
T cells needed to achieve effective killing of cancer cells in
tumors. As such, the tumor vasculature contributes to the hall-
mark capability of evading immune destruction by its inability
to support intensive T cell inflammation. Numerous studies
have documented this barrier to T cell influx, seen by the
absence in tumors of high endothelial venules (HEVs) (Onrust
et al., 1996), vascular structures serving as portals for mass
transit of lymphocytes into and out of activated lymph nodes
and heavily inflamed tissues. More recently, regulatory signals
that render tumor vasculature nonpermissive for HEVs and
such mass transit of CTLs have been identified, and their modu-
lation was found to break down inflammatory barriers (Fisher
et al., 2011; Manzur et al., 2008). Thus, an added benefit of ‘‘anti-
angiogenic’’ strategies involving inhibition of VEGF signaling and
of its consequent vascular abnormalities may be in enabling
tumor immunity via HEV induction in the normalized vasculature
(Goel et al., 2011; Manzur et al., 2008).
Infiltrating Immune Cells. IIC phenotypes in some tumors are
similar to the resolution phase of wound healing, wherein the
TME contains significant leukocytic infiltrations that convey
immunosuppressive activity (ability to block antitumor CTL or
NK/T cell-mediated killing of aberrant cells). These assemblages
include regulatory T cells (Treg), iMCs/MDSCs, TAMs pro-
grammed by Th2-type cytokines, and neutrophil and mast cell
subtypes that collectively endow cancer cells with a mechanism
to escape killing by T cells (Ruffell et al., 2010).
Macrophage progenitors exposed to a variety of immune-
regulatory cytokines (IL-4, IL-13, etc.) and other factors (thymic
stromal lymphopoietin, immune complexes, etc.) can differen-
tiate to become alternatively activated TAMs with various
tumor-promoting properties, as elaborated above. Among their
distinctive phenotypes is absence of cytotoxic activity typified
by conventional tissue macrophages (Qian and Pollard, 2010),
instead manifesting an ability to block CD8+ T cell proliferation
or infiltration though release of factors with immunosuppressive
potential (Denardo et al., 2011; Doedens et al., 2010; Kryczek
et al., 2006; Movahedi et al., 2010). TAMs also indirectly foster
immune suppression through recruitment of Treg cells via the
chemokine CCL22 (Curiel et al., 2004). In murine tumor models,
suppression of CD8+ T cell proliferation by TAMs is at least partly
dependent on metabolism of L-arginine via arginase-1 or iNOS
(Doedens et al., 2010; Movahedi et al., 2010) resulting in produc-
tion of oxygen radicals or nitrogen species (Lu et al., 2011b;
Molon et al., 2011). In human TAMs, suppression of CD8+
T cells can occur independent of L-argininemetabolism (Kryczek
et al., 2006) and may instead rely on macrophage expression of
ligands for T cell costimulatory receptors that mediate T cell inhi-
bition (Topalian et al., 2012), as has been described for hepato-316 Cancer Cell 21, March 20, 2012 ª2012 Elsevier Inc.cellular (Kuang et al., 2009) and ovarian (Kryczek et al., 2006)
cancer. Data from human tumors indicate that the presence of
TAMs expressing immune-suppressive markers correlates with
reduced survival of patients with several types of solid tumors,
and notably inversely correlates with CD8+ T cell density in
human breast cancer (Denardo et al., 2011).
iMCs encompass a diverse population of myeloid cells char-
acterized in part by coexpression of surface markers CD11b
and Gr1, and include monocytes variably referred to as MDSCs,
inflammatory monocytes, and neutrophils (Ostrand-Rosenberg,
2008). MDSCs and iMCs are functionally characterized by their
suppression of T cell proliferation via arginase I, inducible nitric
oxide synthase expression, and perioxynitrite, and, at the
same time, by their ability to promote generation of Treg cells
(Ostrand-Rosenberg, 2008).
While the immunosuppressive activity of mast cells is not well
described, it is clear that in addition to their prominent mitogenic
and proangiogenic activities as discussed above, they also indi-
rectly regulate immunosuppression (Wasiuk et al., 2009), by
releasing cytokines that recruit CTL-suppressing MDSCs and
Tregs. Tregs are also recruited into neoplastic tissues by other
cytokines, most notably CCL2 and TGF-b; their abundance
(and hence their indictment as tumor promoting) correlates
with poor outcome for several cancer types (van der Vliet et al.,
2007). Tregs typically play an important physiological role in sup-
pressing responses to self-antigens, thereby preventing autoim-
munity, and as such can be corrupted to dampen anti-tumor
immunity. A related immunosuppressive strategy involves
expression of the lymphatic chemokine CCL21 in tumors;
CCL21 instructs lymphoid neogenesis and immune tolerization
involving MDSCs and Tregs so as to prevent autoimmunity;
thus, when CCL-21 is ectopically expressed in tumors, it can
contribute to suppression of antitumor immunity by altering the
differentiation and function of IICs, biasing toward tumor-
promoting subtypes (Shields et al., 2010).
Cancer-Associated Fibroblastic Cells. In addition to producing
chemokines and other signals that recruit IICs, CAFs can
demonstrably inhibit cytotoxic T cells and NK/T cells, in part by
producing TGF-ß, thereby blunting destructive inflammatory
responses that might otherwise disrupt tumor growth and
progression (Stover et al., 2007).
Reprogramming Energy Metabolism
There is now broad appreciation that cancer cells have altered
metabolism to support chronic proliferation, in particular, flexible
utilization of fuel sources and modes of consuming them to
generate energy and biomaterials; most notable is the activation
of aerobic glycolysis that complements the output of (sometimes
reduced) oxidative phosphorylation for such purposes. While
much of metabolic reprogramming is considered to be cell
intrinsic to the cancer cells, there are both evident and emergent
extrinsic modulators in the TME.
Angiogenic Vascular Cells. Variations in the density and func-
tionality of the angiogenic tumor vasculature are well-estab-
lished modulators of energy metabolism for the cancer cell; in
particular, inadequate vascular function can result in hypoxia,
activating the HIF response system, which among its myriad of
effects can stimulate aerobic glycolysis, enabling cancer cells
to survive and proliferate more effectively in conditions of
vascular insufficiency, thereby concomitantly enhancing the
capability for invasive growth. It is of course arguable whether
this effect on metabolism truly represents a functional contribu-
tion of tumor vasculature to the cancer cell and hence to malig-
nant phenotypes, as opposed to a reaction to its impaired
functionality, but the net result remains the same, that the nature
of the aberrant vasculature of the TME impacts cancer cell
metabolism.
Infiltrating Immune Cells. A specific role for IICs as regulators
of altered energy metabolism in cancer cells is beginning to
emerge (Trinchieri, 2011). While definitive genetic studies unam-
biguously linking IICs to tumor cell metabolism are still on the
horizon, it has been reported that alternatively activated macro-
phages are implicated in the altered metabolism of tumors, as
well as in the development of metabolic pathologies (Biswas
and Mantovani, 2012).
Cancer-Associated Fibroblastic Cells. There is an intriguing
line of evidence linking CAFs to an unconventional form of
aerobic glycolysis, in which CAFs are induced by reactive
oxygen species released by cancer cells to switch on aerobic
glycolysis, secreting lactate and pyruvate that, in turn, can serve
as fuel for cancer cell proliferation (Rattigan et al., 2012; Sotgia
et al., 2012). A particular subclass of CAF, in which the intracel-
lular scaffold protein Caveolin-1 is downregulated (by reactive
oxygen species), displays this metabolic support phenotype,
resulting in an activated TME that drives early tumor recurrence,
metastasis, and poor clinical outcome in breast and prostate
cancers (Sotgia et al., 2011). While yet to be generalized, the
results (and the association of reduced Caveolin-1 in CAFs
with poor prognosis) suggest that heterotypic supply of energy
sources to cancer cells may prove to be yet another profound
contribution made by CAFs to the TME, above and beyond the
aforementioned roles in orchestrating cell proliferation (and
survival), angiogenesis, invasion, and metastasis.
Recent data have also revealed that adipocytes similarly
engage in ‘‘metabolic coupling’’ with cancer cells and thereby
promote tumor progression (Martinez-Outschoorn et al., 2012)
(Nieman et al., 2011). Metastatic ovarian carcinoma typically
seeds into adipose tissue in peritoneum, resulting in reprogram-
ming of proximal adipocytes toward a more catabolic state. In
this state, ‘‘activated’’ adipocytes generate free fatty acids that
are utilized by metastatic ovarian cancer cells to generate ATP
via mitochondrial b-oxidation. Mitochondrial metabolism in
metastatic ovarian cancer cells is fostered, thereby protecting
them from apoptotic cell death, as well as improving chemore-
sistance, and enhancing their colonization into macrometastatic
lesions (Nieman et al., 2011). Looking ahead, it will be interesting
to determine if re-educated adipocytes are involved in tumor
metabolism in other cancer types, perhaps in partnership with
conventional fibroblast-derived CAFs, which as noted above
are implicated in metabolic fueling of breast cancer cells (Sotgia
et al., 2012).
Thus, a remarkable symbiotic relationship in energy metabo-
lism is emerging between CAFs and cancer cells, in which
CAFs in different TMEs can exchange energy sources with
cancer cells to optimize metabolic efficiency and tumor growth,
involving the alternative use of glucose and lactate, and other
energy-richmolecules. The nature of the symbiosis can evidently
vary depending on the TME: in some cases, the CAFs switch on
aerobic glycolysis, utilizing glucose and secreting lactate that istaken up by cancer cells and used as fuel (Balliet et al., 2011;
Ertel et al., 2012; Martinez-Outschoorn et al., 2012; Sotgia
et al., 2012). In other cases, the symbiosis is opposite: cancer
cells switch on aerobic glycolysis, utilizing glucose and exporting
lactate, which the CAFs then take up and use as fuel to drive their
tumor-promoting functional activities (Rattigan et al., 2012). No
doubt further variations of the energy-sharing theme, and intrica-
cies of mechanism, will be revealed as other TMEs are assessed
for their metabolic phenotypes.
Beyond The Hallmarks: Supporting Cancer Stem Cells
It has become evident in the past decade that most if not all
malignancies contain a heterogeneous subpopulation of cancer
cells with stem-like properties—cancer stem cells (CSCs)—that
are instrumental in the pathologic manifestation of cancer, vari-
ably affecting initiation, persistence in the face of intrinsic
barriers to expansive proliferation, metastatic progression, and
the ability to rebound from ostensibly efficacious cancer thera-
pies. Once again, this crucial dimension of the cancer cell is
not strictly autonomous; rather, stromal cells demonstrably
support CSCs. All three stromal cell classes have been impli-
cated in functional support of CSCs in different neoplastic
contexts, including, for example, (1) endothelial cells, pericytes,
and perivascular IICs organized into specialized vascular niches
in primary tumors (Calabrese et al., 2007) as well as metastatic
sites (Kaplan et al., 2005; Lyden et al., 2001; Psaila and Lyden,
2009), and (2) the myofibroblastic/MSC subtype of CAFs, likely
also present in metastatic vascular stem cell niches (Kidd
et al., 2009; Korkaya et al., 2011; Liu et al., 2011; Spaeth et al.,
2008, 2009); similar niche-forming cells may also nurture CSCs
inside primary tumors.
In sum, there is compelling evidence for the insidious roles that
normal cells play in cancer, having been recruited and/or acti-
vated to serve as members of corrupt TMEs, contributing to
the functional capabilities embodied in most of the hallmarks
of cancer (Figure 1). Their contributions are diverse and variable
from one organ and oncogenic foundation in cancer (stem) cells
to another. The three general classes of stromal cell contain
multiple cell types and subcell types, of which major subtypes
and their ascribed functions (in various neoplastic contexts) are
summarized in Figure 2.
Challenges in Charting Human Tumor
Microenvironments
Much of the functional and correlative evidence presented above
implicating stromal mechanisms has come from experiments
performed in model systems, principally tumors growing and
progressing in genetically engineered mouse models of cancer
(GEMM) and human xenotransplant mice (increasingly now
primary patient-derived xenotransplants [PDX]), as well as in
cell and organ coculture assays. Moreover, the challenges
in performing precise genetic manipulations of stromal cells in
experimental tumors is considerable, and as such, some of the
predicted contributions have not been definitively established
in terms of their functional significance in relation to the driving
forces embodied in the mutationally transformed cancer cells.
And even then, a bigger question remains: do human cancers
and their foundation in cancer cells (and cancer stem cells)
develop, progress, metastasize, and acquire drug resistance
with similar support by accessory cells recruited and redirectedCancer Cell 21, March 20, 2012 ª2012 Elsevier Inc. 317
Figure 2. Multiple Stromal Cell Types and Subcell Types of the Tumor Microenvironment Can Variably Contribute to, or in Some Cases
Oppose, Acquisition of the Seven Hallmark Functional Capabilities in Different Organ Sites, Tumor Types and Subtypes, and Stages of
Progression
Major stromal cell subtypes are indicated, along with a synopsis of key functional contributions that such cell subtypes can make. The antagonistic functions of
certain subcell types are highlighted in gray. The lists of subtypes and of their key functions are not comprehensive, but rather prominent examples. Not listed are
molecular regulatory signals for, and effector agents of, the noted functions. Both lists will certainly be refined in coming years. Also not shown are the crucial
cancer cells and cancer stem cells, with which these stromal cells dynamically interact to manifest cancer phenotypes (Hanahan and Weinberg, 2011). Th2,
helper type 2; CD4 T cell, CD4-positive lymphocyte; Treg, regulatory T cell; CTL, cytotoxic T lymphocyte; NK/T, natural killer and natural killer T cell; MDSCs,
myeloid-derived suppressor cells; aSMA, alpha smooth muscle actin; MSCs, mesenchymal stem cells.to constitute an essential TME? And, how can their roles and
functional importance be clarified across the broad spectrum
of human malignancies, factoring in differences to the histologi-
cally distinct stages of tumor development and progression, the
molecular genetic subtypes being recognized for many human
cancers, and the individual patient to patient variations that are
increasingly appreciated? Certainly, there is epidemiological
evidence associating abundance of particular stromal cell
types—density of neovascularization and abundance of tumor-
promoting versus tumor antagonizing IICs—with prognosis in
various human cancers (Balkwill and Mantovani, 2011). Beyond
epidemiology, the path toward clarification is challenging. One
possible approach may involve integration of representative
mouse models of particular cancers (GEMM and PDX) with
morphology-retaining biopsies and surgical resections from318 Cancer Cell 21, March 20, 2012 ª2012 Elsevier Inc.cancer patients: hypotheses and knowledge developed via
functional studies in mouse models could be validated by
analyzing the primary human samples for predicted determi-
nants indicative of functional correlation. Among the analytic
techniques that can be envisioned are (1) advanced histochem-
ical methodology (multicolor immunostaining and in situ RNA
hybridization); (2) precise laser capture microdissection of
stromal cell types and subtypes populating lesions, facilitated
by selective antibody capture, followed by bimolecular analysis,
including deep sequencing of mRNA and miRNA; and (3) purifi-
cation by flow cytometry—also using antibody and other cell
surface identifiers—of viable stromal subcell types, followed
by cell bioassays and molecular genetic analyses, again
leveraging tools and knowledge from the model system(s) to
ask if the human lesion manifests similar stromal cells and
functional effectors. Crosstalk and coordinated signaling path-
ways between neoplastic cells and stromal cell types identified
in mouse models seem likely to prove indicative of similar (if
not identical) interactions operating in cognate human tumors,
but the challenge will be to establish the correlation. Initial glimp-
ses into the power of evaluating human tumor stroma for risk
prediction has provided tantalizing information indicating that
aspects of the TME significantly correlate with overall survival,
as well as response to therapy (Beck et al., 2011; Denardo
et al., 2011; Finak et al., 2008). Advancements in noninvasive
imaging and analysis of blood-borne tumor-derived material
may also prove of value for profiling the constituents of the tumor
stroma (Daldrup-Link et al., 2011; Weissleder, 2006). The future
challenge is considerable, but the imperative to pursue it is clear,
as there is little doubt that the TME and its conscripted stromal
cells will prove to be instrumental factors in many human malig-
nancies.
Prospects and Obstacles for Therapeutic Targeting
of Function-Enabling Stromal Cell Types
The demonstrable roles that stromal cells can in principle play in
enabling or enhancing multiple hallmark capabilities (Figures 1
and 2) in different TMEs clearly motivates therapeutic targeting
strategies aimed to abrogate their contributions. The task,
however, will not be easy. A case in point involves antiangiogenic
therapy, anticipated for decades as a paradigm-shifting
approach to treating human cancer, by abrogating an essential
hallmark capability. Potent angiogenic inhibitors have been
developed, principally aimed at the VEGF and other proangio-
genic signaling pathways. Several such drugs have successfully
surpassed the efficacy bar in phase 3 clinical trials, and are
consequently approved for use in particular cancer indications,
representing a proof of principle that a hallmark-enabling stromal
cell type is a valid therapeutic target. The reality check, however,
is that clinical responses are typically transitory, and survival
benefit limited in duration, indicative of the development of adap-
tive resistance; the explanation is likely multifactorial, based on
preclinical studies in mouse models, which have revealed in
some cases evasion of the signaling blockage (Casanovas
et al., 2005), in others recruitment of additional or different
subtypes of proangiogenic IICs or CAFs (Priceman et al., 2010;
Shojaei et al., 2007), and in others shifting to heightened depen-
dence on invasion and metastasis to co-opt normal tissue
vasculature instead of producing a neovasculature (Ebos and
Kerbel, 2011; Pa`ez-Ribes et al., 2009; Sennino et al., 2012).
While sobering, such results nevertheless suggest solutions: if
mechanisms of adaptive-evasive resistance to antiangiogenic
therapy that are operative in particular cancer types can be iden-
tified and cotargeted, perhaps antiangiogenic therapy in such
cancers can be rendered more enduring. There is similar
promise, and likely pitfalls, in targeting CAFs and specific IIC
subtypes, in regard to the goal of short-circuiting the multiple
functional contributions they make to hallmark capabilities.
One can anticipate both beneficial effects, and adaptive resis-
tance. In regard to targeting tumor-promoting IICs, there are
both encouraging examples (Denardo et al., 2011; Giraudo
et al., 2004; Mazzieri et al., 2011; Pietras et al., 2008; Shree
et al., 2011), and sobering cases of adaptive resistance,
including substitution of a targeted subtype by another withredundant capabilities (Casanovas, 2011; Pahler et al., 2008).
Here again, identification of resistance mechanisms may enable
combinatorial strategies that counteract adaptive resistance
when targeting CAFs and IICs and their functional contributions
to hallmark capabilities, improving therapeutic efficacy. Such
promise, however, may be qualified by yet another confounding
complexity that will likely need to be addressed: individual
patient heterogeneity. Thus, it may prove instrumental to factor
into the equation individual variations in tumors from different
patients. While ostensibly of the same type and histological
and/or molecular genetic subtype, individual tumors may never-
theless have profound (and subtle) differences —in cancer cells
and likely in the character or abundance of stromal cell (sub)-
types that impact critical attributes of the TME, thereby conse-
quently determining the extent of beneficial responses to
mechanism-guided therapeutic (co)-targeting; this emerging
realization is spawning the frontier of personalized cancer
therapy (Haber et al., 2011; Martini et al., 2011). As alluded
above, technology development and more routine protocols
for informative tumor biopsy may allow the precise constitution
of function-enhancing/enabling stromal cell types in a patient’s
(primary and/or metastatic) TME to be revealed, allowing fine
tuning of therapeutic strategies with greater potential for benefi-
cial impact on the disease.Conclusions
Cancer medicine is increasingly moving toward a new era of
personalized diagnostics and therapeutics that aggressively
embraces integrative approaches (De Palma and Hanahan,
2012). Looking forward, combinatorial strategies will target not
only cancer cell-intrinsic pathways, but also cancer cell-extrinsic
cells, pathways, and mediators at play in the TME. As the stra-
tegic goal of deciphering the roles of the TME in primary and
metastatic tumor locales progresses, new discoveries can be
envisioned to produce innovative multitargeting strategies that
will be able to more thoroughly extinguish primary and meta-
static disease, while circumventing elucidated adaptive resis-
tance mechanisms to such therapies, profoundly altering
the prognosis for many forms of human cancer (De Palma and
Hanahan, 2012).ACKNOWLEDGMENTS
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